AviadoBio, a pre-clinical stage platform company with operations in the UK and the US and backed by NEA, F-Prime, and J&J Innovation and focused on developing and delivering transformative gene therapies for people with neurodegenerative disorders, has appointed Jeff Goater as Chair of its Board of Directors.
Jeff brings more than 20 years of biotech and Wall Street experience to this appointment. Currently, Jeff is a Venture Partner at The Column Group and interim CEO of Atavistik Bio. Previous roles include CEO of Surface Oncology and Managing Director at Evercore Partners.
Jeff holds graduate degrees in immunology, pathology, and business administration from the University of Rochester. He currently serves on the boards of Atavistik, Judo Bio, Kallyope, Ribon Therapeutics, and Surface Oncology.
With Occam having also placed Lisa Deschamps as CEO at AviadoBio in 2021, we are pleased to extend our relationship at the Board level.
About Occam Global
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the globe.